Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study by Liao, Christopher CL et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Liao et al. World Journal of Surgical Oncology 2010, 8:33
http://www.wjso.com/content/8/1/33
Open Access RESEARCH
BioMed  Central
© 2010 Liao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research Analysis of post-operative changes in serum 
protein expression profiles from colorectal cancer 
patients by MALDI-TOF mass spectrometry: a pilot 
methodological study
Christopher CL Liao1,2, Anuja Mehta2, Nicholas J Ward1,2, Simon Marsh1, Tan Arulampalam1 and John D Norton*2
Abstract
Background: Mass spectrometry-based protein expression profiling of blood sera can be used to discriminate 
colorectal cancer (CRC) patients from unaffected individuals. In a pilot methodological study, we have evaluated the 
changes in protein expression profiles of sera from CRC patients that occur following surgery to establish the potential 
of this approach for monitoring post-surgical response and possible early prediction of disease recurrence.
Methods: In this initial pilot study, serum specimens from 11 cancer patients taken immediately prior to surgery and at 
approximately 6 weeks following surgery were analysed alongside 10 normal control sera by matrix-assisted laser 
desorption ionisation time of-flight-mass spectrometry (MALDI-TOF MS). Using a two-sided t-test the top 20 ranked 
protein peaks that discriminate normal from pre-operative sera were identified. These were used to classify post-
operative sera by hierarchical clustering analysis (Spearman's Rank correlation) and, as an independent 'test' dataset, by 
k-nearest neighbour and weighted voting supervised learning algorithms.
Results: Hierarchical cluster analysis classified post-operative sera from all six early Dukes' stage (A and B) patients as 
normal. The remaining five post-operative sera from more advanced Dukes' stages (C1 and C2) were classified as 
cancer. Analysis by supervised learning algorithms similarly grouped all advanced Dukes' stages as cancer, with four of 
the six post-operative sera from early Dukes' stages being classified as normal (P = 0.045; Fisher's exact test).
Conclusions: The results of this pilot methodological study illustrate the proof-of-concept of using protein expression 
profiling of post-surgical blood sera from individual patients to monitor disease course. Further validation on a larger 
patient cohort and using an independent post-operative sera dataset would be required to evaluate the potential 
clinical relevance of this approach. Prospective data, including follow-up on patient survival, could in the future, then 
be evaluated to inform decisions on individualised treatment modalities.
Background
Treatment options for colorectal cancer (CRC) patients
are still largely reliant on traditional staging criteria [1].
For early stage (Dukes' A; Stage I) patients, surgery alone
offers the best prospect for cure [2]. For patients with
advanced disease (Dukes' C1, C2 and D; Stages III or IV)
with lymph node involvement or distant metastasis, there
are established survival benefits of adjuvant chemother-
apy [3,4]. Controversy still exists however, in optimum
treatment modality for the 30% of patients who present
with Dukes' B/Stage II disease [5-7]. Although 25 - 30% of
these patients will develop recurrent disease, the decision
to implement adjuvant chemotherapy is often made on
the basis of additional perceived risk factors in an attempt
to minimise chemotherapy-related morbidity [8]. There
is therefore a long-recognised need for more robust crite-
ria in patient stratification of the heterogeneous group of
Dukes' B/Stage II patients.
In recent years, molecular markers present in patients'
tumour cells have become established as centre-stage in
the quest for improved cancer sub-group classification
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with the ultimate aim of developing individualised thera-
peutic regimes [9]. In CRC, markers based on microsatel-
lite instability (MSI) and loss of heterozygosity at 18q
have shown prognostic significance [10-13]. Of more spe-
cific relevance, gene-expression profiles based on 23- and
7-gene signatures are reportedly predictive for high risk
of recurrence in Stage II disease [14-16].
More latterly, attention has focussed on analysis of the
blood serum proteome as a potential source of tumour
markers for disease diagnosis. By using matrix-assisted
laser desorption-ionisation time of-flight-mass spec-
trometry (MALDI-TOF MS) or surface-enhanced laser
desorption-ionisation time-of-flight mass spectrometry
(SELDI-TOF MS), peptide fragments representing diag-
nostic molecular signatures from several types of cancer
have been identified in blood sera/plasma that discrimi-
nate cancer patients from normal individuals [17-20]. In
CRC, the sensitivity and specificity of this approach
reportedly ranges from 90 - 95% [14,17,19,21-24]. Impor-
tantly, analysis of the diagnostic 'peptidome' of patients'
blood serum is amenable to repeated sampling and might
potentially be used to monitor disease course following
surgery with the aim of predicting disease recurrence.
We report here the results of an initial pilot method-
ological study in which MALDI-TOF MS analysis of
blood sera from a cohort of 11 colorectal cancer patients
was performed immediately prior to and at approxi-
mately 6 weeks post-surgery (the usual time for com-
mencement of adjuvant chemotherapy). The post-
operative serum peptidome profile of patients who ini-
tially presented with early stage disease and who would
be expected to experience long-term disease-free sur-
vival, mostly reverted to a more normal pattern. By con-
trast, the post-operative serum profiles of patients
presenting with more advanced disease retained features
more characteristic of cancer patients.
Methods
Serum samples
10 ml samples of venous peripheral blood were obtained
from 10 healthy volunteers and from 11 patients diag-
nosed with CRC one day before their scheduled surgery
and at approximately six weeks following surgery. All
specimens were obtained with informed consent in
accordance with UK NHS Research Ethics procedures
(Protocol reference MH 528). Blood samples were col-
lected using a sterile 'vacutainer' and were allowed to
coagulate at room temperature. After 3 hours, samples
were centrifuged at 1752 × g for 5 minutes and the sera
recovered and filtered through a 0.45 μm 'minisart' SRP
(Sartorius) membrane filter prior to being stored at -
80°C. Table 1 summarises the Dukes' and TNM staging of
the 11 patients studied.
Serum protein processing
In addition to following a strict regimen for sample col-
lection and storage to minimise pre-analytical factors
(above), subsequent processing steps were standardised
in order to minimise possible between-sample variation.
Following a single cycle of thawing, serum protein purifi-
cation was performed on all samples in parallel by
reverse-phase hydrophobic interaction chromatography
using 'C8 MB-HIC' magnetic beads (Bruker Daltonics,
Germany) following the manufacturer's instructions
except that protein was eluted with 20 ul of 50% ace-
tonitrile (Fisher Scientific UK). Eluted protein (20 ul) was
mixed with 20 μl of 20 mg/ml of matrix, 2', 4', 6' - trihy-
droxy-acetophenone monohydrite (Fluka) in 50% ace-
tonitrile and adjusted to 200 mM diammonium citrate.
Slow co-crystallization [25] was performed at 21°C on an
orbital shaker (1000 rpm) for four hours. Recovered crys-
tals were washed with water and then deposited on a
stainless steel MALDI target plate (Bruker Daltonics,
Germany).
MALDI-TOF mass spectrometry
Spectra were acquired on all samples in parallel using a
MALDI-TOF mass spectrometer (Reflex IV; Bruker Dal-
tonics) with the following settings: ion source 1, 20 kV;
ion source 2, 16.65 kV; lens voltage 9.5 kV; pulsed ion
extraction, 200 ns. Ionisation was achieved by irradiation
with a nitrogen laser (ë = 337 nm) operating at 25 Hz and
35% laser power. For matrix suppression, we used a high
gating factor with signal suppression up to 1000 Da. Mass
spectra were detected in linear positive mode. Detector
gain was set at 1600 V, sample rate at 1.0 and electronic
gain at 100 mV with real-time smoothing. Spectra were
acquired in duplicate from a single protein sample from
each specimen from 500 shots delivered as 5 × 100
pulses. All protein peaks with signal-to-noise (S/N) ratio
>3 in the mass range 1 - 20 kDa were recorded with the
use of the 'AutoXecute' tool of the 'flexAnalysis' acquisi-
tion software (Version 2.0; Bruker Daltonics). Spectra
were externally calibrated using neurotensin and soma-
tostatin (Sigma-Aldrich) as peptide calibrants. and were
normalised using total ion current to determine the rela-
tive intensities if spectral peaks.
Data Processing and analysis
Aligned spectra were exported as ASCII files and were
digitally processed by smoothing (low pass filter), adap-
tive background correction and high pass filter before
peak matching by using a mixture of Gaussians optimised
by model-based clustering [26,27]. These and subsequent
analysis were implemented in the 'GenePattern' (Broad
Institute, MIT, USA) suite of software tools [28]. Using a
two-sided t-test, the top 20 ranked protein peaks that dis-
criminate normal from pre-operative CRC sera wereLiao et al. World Journal of Surgical Oncology 2010, 8:33
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identified from the 356 aligned spectral peaks by using
the 'ComparativeMarkerSelection' module [29]. Hierar-
chical clustering [30] utilised Spearman's rank correlation
with pairwise complete linkage. Weighted voting and k-
nearest neighbours (k-NN) classifiers [31] were used to
generate predictive models using spectral data from nor-
mal and pre-operative colorectal cancer sera as a 'train-
ing' set which were then applied to the post-operative
sera spectra as an independent 'test' dataset. Alterna-
tively, the post-operative sera were classified as either
cancer or normal by using the predictive algorithms in an
iterative, 'leave-one-out cross validation' mode [32].
Results
The raw spectral data used for analysis of all 32 serum
samples is shown in Additional file 1. A set of 20 top-
ranked marker peaks that discriminate between sera
from the pre-operative cancer and the normal control
groups was used for hierarchical cluster analysis (Figure
1). Six of the post-operative sera samples that belonged to
early Dukes' stages A and B (PO1- PO4, PO9, PO11) were
grouped with the normal controls (N) while the remain-
ing five post-operative sera from more advanced Dukes'
stages C1 and C2 (PO5-PO8, PO10) were grouped with
pre-operative cancers (T) (Figure 1).
Figure 2 illustrates how the relative intensities of some
representative discriminating marker peaks change in
post-operative sera. The 8361.7 Da peak which is up-reg-
ulated in pre-operative CRC sera showed a marked
down-regulation in most patients following surgery (Fig-
ure 2A). The 3466.6Da peak which is down-regulated in
pre-operative CRC sera compared to normals was vari-
ably up-regulated in post-operative CRC sera (Figure 2B).
By contrast, the 2270.3Da peak showed only borderline
changes in post-operative compared to pre-operative sera
(Figure 2C).
Spectra from the 10 normal controls and 11 pre-opera-
tive cancer sera were then used as a training dataset to
generate predictive models for assigning an unknown
serum spectrum to either the normal or cancer group.
Table 1: Clinico-pathological features of patient specimens.
1T 2PO Age Gender Dukes' 
stage
3TNM stage Differentiation Vascular 
invasion
4LNs 
harvested
4LNs 
positive
T1 PO1 84 F B pT4, pN0, pR0 Moderate Absent 15 0
T2 PO2 82 M A pT2, pN0, pR0 Moderate Absent 9 0
T3 PO3 77 M B pT3, pN0, pR0 Poor Absent 6 0
T4 PO4 71 F A pT2, pN0, pR0 Moderate Present 11 0
T5 PO5 79 M C1 pT3, pN1, pR0 Poor Absent 23 3
T6 PO6 79 M C1 pT4, p N1, pR0 Poor Absent 15 3
T7 PO7 62 F C2 pT2, pN2, pR0 Moderate Present 14 8
T8 PO8 65 F C2 pT4, pN1, pRx Well to Mod Present 15 2
T9 PO9 74 M B pT4, pN0, pMx, pRx Moderate Absent 7 0
T10 PO10 69 M C1 pT3, pN2, pR0 Moderate Absent 12 5
T11 PO11 62 M B pT3, pN0, pR0 Moderate Absent 32 0
1T = Pre-operative specimen; 2 PO = Post-operative specimen (six weeks following surgery); 3TNM stage = Tumour-Node-Metastasis classification 
where p = pathological stage, T1 = tumour invades submucosa, T2 = tumour invades muscularis propria, T3 = tumour invades subserosa, T4 = 
tumour breaches serosa and invades adjacent organ, N0 = no lymph nodes involved, N1 = 1-3 lymph nodes involved, N4 = four or more lymph 
nodes involved, R0 = resected margin free of cancer, Rx = resected margin not assessed, Mx = metastisis not assessed; 4LNs = lymph nodesLiao et al. World Journal of Surgical Oncology 2010, 8:33
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When applied to the post-operative sera spectra as an
independent 'test dataset', both the Weighted voting and
k-NN classifiers assigned the post-operative sera from the
two Dukes' stage A patients (PO2, PO4) and two of the
four Dukes' stage B patients (PO1, PO3) to the normal
group, while the remaining two Dukes' stage B post-oper-
ative sera (PO9, PO11) were assigned to the cancer group
(Table 2). All post-operative sera from more advanced
Dukes' stage patients were classified as belonging to the
cancer group. Identical results were obtained when the
predictive algorithms were employed in 'leave-one-out'
cross-validation mode to classify the post-operative sera
spectra (Table 2). The classifier algorithms thus discrimi-
nate between post-operative sera from early (Dukes' A, B)
and advanced (Dukes' C1, C2) stage disease (P = 0.045;
Fisher's exact test).
Discussion
Analysis of the low molecular weight 'peptidome' in cir-
culating blood serum/plasma by mass spectrometry pro-
tein profiling, using either MALDI-TOF MS or SELDI-
TOF MS platforms, has attracted considerable interest as
an approach for diagnosis of common types of cancer
[14,18,32,33]. Few studies have sought to identify exam-
ples of individual diagnostic peptides in the serum of can-
cer patients from the burgeoning number reported by
different laboratories. However, from the limited data
available, such diagnostic peptidome fragments appear to
largely comprise a collection of 'surrogate' tumour mark-
ers that arise from the complex interaction between the
tumour microenvironment and the circulatory system
[18]. Although the reliability/reproducibility of serum
protein profiling by mass spectrometry has been the sub-
ject of much debate, most authorities acknowledge its
potential as a diagnostic aid provided that certain safe-
guards are met [34]. In our study, we followed a stan-
dardised regimen of sample collection, storage and
Figure 1 Classification of spectra from post-operative sera by hi-
erarchical cluster analysis. The top 20 ranked protein peaks that dis-
criminate normal from pre-operative CRC sera were used in 
hierarchical cluster analysis employing Spearman's rank correlation as 
column distance measure with pair-wise complete-linkage as the clus-
tering method. The identities of serum specimens (see Table 1) are de-
picted in the dendrogram (N = normal, T = pre-operative cancer, PO = 
post-operative cancer). The Dukes' stage of each patient prior to sur-
gery is depicted in the respective post-operative (PO) sample. The m/z 
values and P values (student's t-test) of discriminating peaks are shown 
in the right-hand column.
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Figure 2 Representative expression profiles of discriminating 
peaks. The expression levels (relative ion intensity - arbitrary units) is 
shown for three marker peaks that discriminate between pre-operative 
CRC and normal control sera. The pair-wise profiles of pre-and post-op-
erative sera are grouped according to early Dukes' (A, B) or advanced 
Dukes' (C1, C2) stage. The m/z and level of significance (student's t-
test) for discrimination between pre-operative and normal sera is 
shown for each peak profile in A, B and C.
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processing in order to minimise pre-analytical factors as a
source of between-sample variation.
Some earlier studies of rectal and colorectal cancer
have suggested that serum proteomics profiling may also
yield prognostic information, in addition to potentially
predicting response to treatment. For example, the
changes in serum peptidome profile that occur 1-2 days
following neo-adjuvant therapy in rectal cancer patients
reportedly discriminate good from poor responders with
87.5% sensitivity and 80% specificity [35]. An additional
study has also reported that some minor post-operative
changes in the serum peptidome profile of colorectal can-
cer patients do occur at 2 weeks following surgery,
although their relation to disease status has not been
addressed [36].
In our own studies, we have investigated the application
of serum protein profiling by MALDI-TOF MS for moni-
toring colorectal cancer patients following surgery with a
view to exploring the future potential value of this
approach for guiding individualised adjuvant chemother-
apy. To be clinically useful, 'informative' post-operative
changes would need to be evident prior to the com-
mencement of adjuvant chemotherapy (nominally,
around 6 weeks post-surgery). Therefore, an important
goal of our study was to establish whether significant
changes in post-operative sera could be detected at this
time. We found that 4 out of the 11 patients' post-opera-
t i v e  s e r a  w e r e  c l a s s i f i e d  a s  h a v i n g  r e v e r t e d  t o  n o r m a l
when using prediction classification models that had
been built using the pre-operative cancer sera and normal
Table 2: Classification of post-operative sera by supervised learning
Patient 
sera 
Post-op
Dukes'/TNM 
stage
Classification using tumour verses normal
model
Classification using leave-one-out x-validation
k - N N C o n f .W VC o n f . k - N N C o n f .W V C o n f .
PO1 B (pT3) N 0.3828 N 0.4044 N 0.0723 N 0.3997
PO2 A (pT2) N 0.6741 N 0.3174 N 0.2472 N 0.0249
PO3 B (pT3) N 0.0891 N 0.0448 N 0.2052 N 0.1
PO4 A (pT2) N 0.3015 N 0.8506 N 0.4608 N 0.2614
PO5 C1 (pT3, pN1) T 0.11 T 0.2675 T 0.1291 T 0.1098
PO6 C1 (pT4, N1) T 0.418 T 0.3068 T 0.5647 T 0.4638
PO7 C2 (pT2, pN2) T 0.114 T 1.0 T 0.1973 T 0.1213
PO8 C2 (pT4, N1) T 0.7767 T 0.572 T 0.0559 T 0.1747
PO9 B (pT4) T 0.6758 T 0.7736 T 0.5172 T 0.0306
PO10 C1 (pT3, pN2) T 0.234 T 0.2663 T 0.4345 T 0.5141
PO11 B (pT4) T 0.8295 T 0.1734 T 0.5647 T 0.0475
The classification of each post-operative (PO) serum sample as being either normal (N) or cancer (T) is shown together with the confidence 
value (conf.) representing the proportion of 'votes' assigned to the predicted class [25]. The weighted voting (WV) and k-nearest-neighbours 
(k-NN) algorithms were used to classify PO samples either by first generating a predictive model from a training set comprised of normal and 
pre-operative cancer sera or else by 'leave-one-out' cross validation using the complete set of spectra. The feature selection statistics used for 
both algorithms was SNR; distance measure between each feature for the k-NN algorithm was Euclidean.Liao et al. World Journal of Surgical Oncology 2010, 8:33
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control sera profiles as a training dataset. Significantly, all
four of these patients were early Dukes' stage (two stage
A, two stage B). Post-operative sera from an additional
two Dukes' stage B patients together with those of all
Dukes' C1 and C2 patients were classified with the pre-
operative cancer group. Broadly similar results were
obtained using the less stringent hierarchical clustering
classification method, except that all four Dukes' stage B,
together with the two Dukes' stage A post-operative sera
were classified as normal.
Our findings that the diagnostic peptidome signatures
of post-operative sera from early Dukes' stage patients
appear to largely revert to a more normal profile whereas
those from more advanced Dukes' stage patients still
retain predominant characteristics of cancer patients is in
accordance with the expected clinical outcome of the
patient groups; disease-free survival would be expected
for most Dukes' stage A and around half of Dukes' stage B
patients, while more advanced Dukes' stage patients are
more likely to succumb to disease recurrence [1,2,5-8].
However, caution should be exercised in interpreting the
findings from our pilot study since the sample size was
small and the predictive model, which was based on pre-
operative sera from the same patient cohort, utilised a
low sample to feature ratio with the attendant likelihood
of 'overfitting'. On the other hand, the post-operative
spectral dataset was analysed 'blind' and information on
disease stage of patients was not factored in to the predic-
tive model. Nevertheless, in order to assess its clinical rel-
evance, this approach needs to be evaluated on a much
larger patient group and using an independent cohort of
post-operative sera. Our findings should therefore be
viewed only as a pilot methodological study.
Future larger-scale studies may well adopt a different
strategy and would likely be focussed on a smaller num-
ber of informative protein peaks. It would also be highly
desirable to establish the identities of discriminating pro-
tein peaks. This might facilitate the use of a more accu-
rate/reliable quantitation method than that offered by
mass spectral measurements of relative ion intensity.
Finally, a larger-scale study should minimise possible
confounding variables unrelated to cancer status that may
spuriously affect protein peak abundance in repeated
sampling from the same patient.
Further prospective studies of a larger patient group
will also be needed to evaluate whether this approach
could be used to inform clinical decisions on adjuvant
chemotherapy, particularly for Dukes' stage B patients for
whom current pathological staging of tumours is inade-
quate. Longer-term follow-up of post-operative sera by
this approach might also offer the prospect of more reli-
able detection of the onset of disease recurrence than
currently offered by carcinoembryonic antigen (CEA)
[37].
Conclusions
Our preliminary pilot methodological study establishes
the proof-of-concept of using mass spectrometry-based
serum proteomic profiling for monitoring CRC patients
following surgery.
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